What is EVO's current stock price?

EVO (Evotec SE) is currently trading at $3.03 with a market cap of $1.08B.

What sector is Evotec SE in?

Evotec SE (EVO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.

Is EVO a good stock to buy?

Analysts have a Buy consensus on EVO with a price target of $7.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

EVO Evotec SE

Healthcare

$3.03+1.68%ClosedMarket Cap: $1.08B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.28

P/S

1.20

EV/EBITDA

-14.32

DCF Value

$-3.53

FCF Yield

-4.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

11.5%

Operating Margin

-13.9%

Net Margin

-26.0%

ROE

-24.5%

ROA

-11.8%

ROIC

-7.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$159.2M	$-123.9M	$—
Q4 null	$250.9M	$14.5M	$—
FY null	$757.3M	$-99.4M	$—
Q3 null	$163.9M	$-43.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$7.00 - $7.00

1 Strong Buy2 Buy0 Hold0 Sell1 Strong Sell

HC Wainwright & Co.Buy

2025-08-14

Trading Activity

Insider Trades

View All

Anderson Mark Monroedirector

SellThu Nov 01

Anderson Mark Monroedirector:

SellThu Nov 01

Smith Scott Clifforddirector

SellMon Oct 29

Smith Scott Clifforddirector:

SellMon Oct 29

LAFFER ARTHUR Bdirector

SellFri Oct 12

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Exchange

—

Beta

1.30

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Peers